Join the Xalkori group to help and get support from people like you.
Xalkori News
FDA Approves Xalkori (crizotinib) for ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory...
Pfizer’s Xalkori (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
NEW YORK--(BUSINESS WIRE) January 14, 2021 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for...
FDA Expands Use of Xalkori (crizotinib) to Treat ROS-1 Positive Non-Small Cell Lung Cancer
March 11, 2016 – The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1...
Ask a question
To post your own question to this support group, sign in or create an account.